Latest Content

Reviva Pharmaceuticals reveals promising clinical trial data on brilaroxazine, highlighting its potential to treat negative symptoms in schizophrenia.

Explore the complex relationship between epilepsy and psychosis, including forced normalization and treatment strategies for affected patients.

Athletes navigate stress as a performance factor, learning to harness it for optimal results through effective management strategies and support systems.

NTX-253 enters phase 1 trials, exploring a novel approach to schizophrenia treatment with potential for improved safety and efficacy.

Psychiatric Times embraces innovation with interactive digital issues and a new print format, enhancing accessibility for psychiatric clinicians.

Acceptance paves the way for a critical trial of COMP360, a synthetic psilocybin that has the potential to transform PTSD care.

The FDA has granted Breakthrough Therapy designation to Alkermes' alixorexton for narcolepsy type 1, which could offer hope for improved wakefulness and reduced daytime sleepiness.

Cognition Therapeutics shares zervimesine's promising phase 2 results, showing safety and improved symptoms in dementia with Lewy bodies.

Psychiatric Times is adapting to the evolving media landscape, focusing on impactful stories and insights, starting with schizophrenia and lifestyle psychiatry.

These are the 2 winners of the Hanusol Contest!

Explore the intersection of light and darkness through the lens of Hanukkah and the Winter Solstice, revealing insights on peace and human experience.

Explore the vital role of consultation liaison psychiatry in enhancing patient care and emotional well-being in complex medical conditions in our January 2026 theme!